Chemotherapy-related cognitive impairment and kidney dysfunction

Basit Öğe Kaydı
dc.contributor.authorSimeoni, Mariadelina
dc.contributor.authorMulholland, Michele M.
dc.contributor.authorWorkeneh, Biruh T.
dc.contributor.authorCapasso, Anna
dc.contributor.authorCapasso, Anna
dc.contributor.authorHafez, Gaye
dc.contributor.authorLiabeuf, Sophie
dc.contributor.authorMalyszko, Jolanta
dc.contributor.authorMani, Laila-Yasmin
dc.contributor.authorTrevisani, Francesco
dc.contributor.authorDe, Ananya
dc.contributor.authorWagner, Carsten A.
dc.contributor.authorMassy, Ziad A.
dc.contributor.authorUnwin, Robert
dc.contributor.authorCapasso, Giovambattista
dc.contributor.authorCONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target) collaborators
dc.date.accessioned2025-05-28T09:03:45Z
dc.date.available2025-05-28T09:03:45Z
dc.date.issued2025
dc.departmentFakülteler, Eczacılık Meslek Bilimleri Bölümü, Farmakoloji Ana Bilim Dalı
dc.description.abstractCancer and kidney diseases (KD) intersect in many ways resulting in worse outcomes. Both conditions are correlated with cognitive impairment, which can be exacerbated in cancer patients by known effects of many antineoplastic drugs on cognition, leading to a phenomenon known as chemotherapy-related cognitive impairment (CRCI). This manifests as poor attention span, disturbed short-term memory, and general mental sluggishness. This literature review explores CRCI and investigates the potential impact of KD on this phenomenon. Additionally, we highlight the shared pathogenetic mechanisms (including neurotoxicity, neuroinflammation, oxidative stress, vascular disease, electrolyte, and acid-base imbalances), clinical presentation and imaging findings between cognitive impairment in KD and CRCI. The disruption of the blood-brain barrier might be a key mechanism for increased brain permeability to anticancer drugs in nephropathic patients with cancer. Based on existing knowledge, we found a potential for heightened neurotoxicity of antineoplastic drugs and a synergistic potentiation of cognitive impairment in cancer patients with KD. However, further translational research is urgently required to validate this hypothesis.
dc.description.sponsorshipFunding agency: European Cooperation in Science and Technology (COST) Grant number: CA19127
dc.identifier.citationSimeoni, M., Mulholland, M. M., Workeneh, B. T., Capasso, A., Hafez, G., Liabeuf, S., ... & Capasso, G. (2025). Chemotherapy-related cognitive impairment and kidney dysfunction. Nephrology Dialysis Transplantation, 40(Supplement_2), ii54-ii63.
dc.identifier.doi10.1093/ndt/gfae249
dc.identifier.endpageii63
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.issueSupplement_2
dc.identifier.pmid40080088
dc.identifier.scopus2-s2.0-105000229244
dc.identifier.scopusqualityQ1
dc.identifier.startpageii54
dc.identifier.urihttps://hdl.handle.net/20.500.12939/5759
dc.identifier.volume40
dc.identifier.wosWOS:001443929700002
dc.identifier.wosqualityQ1
dc.indekslendigikaynakPubMed
dc.institutionauthorHafez, Gaye
dc.language.isoen
dc.relation.ispartofNephrology, Dialysis, Transplantation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectanticancer drugs
dc.subjectblood–brain barrier
dc.subjectchemotherapy-related cognitive impairment
dc.subjectchronic kidney disease
dc.subjectneurotoxicity
dc.titleChemotherapy-related cognitive impairment and kidney dysfunction
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu